Advertisement


Hope S. Rugo, MD, on Talazoparib for Advanced Solid Tumors: Reduced Hospitalization and Supportive Care

NCCN 2020 Virtual Annual Conference

Advertisement

Hope S. Rugo, MD, of the University of California, San Francisco, discusses an integrated analysis of five clinical trials, in phases I through III, for a variety of advanced cancers. Findings show that patients treated with talazoparib monotherapy had lower hospitalization rates (compared to those receiving chemotherapy) and used less supportive care medication (Abstract CLO20-052).



Related Videos

Head and Neck Cancer
Survivorship

Pam Baker DeGuzman, PhD, on Assessing Distress During Telemedicine Visits With Rural Survivors of Head and Neck Cancer

Pam Baker DeGuzman, PhD, of the University of Virginia School of Nursing, discusses her study findings on the use of the NCCN Distress Thermometer, which identified and addre...

Breast Cancer

Elizabeth Reed, MD, on Helping Providers in Rural Areas Meet the Needs of Younger Patients With Breast Cancer

Elizabeth Reed, MD, of the University of Nebraska Medical Center Fred & Pamela Buffett Cancer Center, talks about how she and her team sought to help rural oncology provi...

Breast Cancer

William J. Gradishar, MD, on Innovating Pathways for Patient Self-Management in Breast Cancer

William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the “4R Model” (Right Information, Care, Patient, and Time) whi...

Breast Cancer

Sara A. Hurvitz, MD, on Talazoparib vs Chemotherapy for Breast Cancer: Results From the EMBRACA Trial

Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses racial differences in self-reported outcomes of patients with HER2-negative, locally advanced or ...

Issues in Oncology

Barbara DeVivo, PhD, MBA, on Tumor Boards: The Influence of Social Hierarchy on Cancer Treatment Decision-Making

Barbara DeVivo, PhD, MBA, of Westmont College, talks about how the culture and structure of tumor boards—and their invisible status hierarchies—may hamper collaboration and i...

Advertisement

Advertisement



Advertisement